Mar 3, 2026 08:00AM
Feb 2, 2026 09:27AM
Jan 14, 2026 08:00AM
Jan 2, 2026 08:00AM
Dec 2, 2025 09:53AM
Nov 17, 2025 08:00AM
Oct 17, 2025 08:26AM PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Oct 16, 2025 08:04AM
Oct 16, 2025 08:00AM
Oct 15, 2025 08:00AM
Oct 8, 2025 08:00AM
Aug 27, 2025 08:00AM
Aug 14, 2025 08:02AM
Aug 14, 2025 08:00AM PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
Aug 11, 2025 09:51AM
Aug 11, 2025 09:49AM
Aug 11, 2025 09:26AM
Aug 11, 2025 09:26AM
Jun 18, 2025 08:00AM
Mar 3, 2025 08:00AM
Sep 19, 2024 08:00AM PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
Aug 28, 2024 08:00AM
Aug 19, 2024 08:00AM
May 15, 2024 08:00AM
May 1, 2024 08:50AM
May 2, 2023 07:30AM
Apr 3, 2023 07:00AM
Mar 29, 2023 07:30AM PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
Feb 7, 2023 07:59AM
Feb 6, 2023 08:00AM
Feb 2, 2023 07:30AM
Feb 1, 2023 11:25AM
Jan 18, 2023 08:15AM
Jan 11, 2023 08:15AM
Dec 15, 2022 07:59AM PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
Nov 14, 2022 07:59AM
Nov 1, 2022 07:00AM
Oct 5, 2022 07:00AM
Sep 29, 2022 07:00AM
Sep 16, 2022 07:00AM
Sep 7, 2022 07:00AM
Jul 13, 2022 07:00AM PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders
Jun 29, 2022 07:00AM
Jun 7, 2022 07:00AM
May 25, 2022 07:00AM
May 5, 2022 07:00AM
Apr 25, 2022 05:06PM
Apr 12, 2022 07:00AM
Mar 23, 2022 07:00AM PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
Feb 16, 2022 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All